nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

18.11.2022 | Original Article

The crosstalk between LINC01089 and hippo pathway inhibits osteosarcoma progression

verfasst von: Hao Zhang, Lin Zhou, Shaopu Hu, Wei Gu, Zhiqiang Li, Jun Sun, Xiaoen Wei, Yongjun Wang

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Osteosarcoma is the most common malignancy in children, with high morbidity worldwide. Researches indicated that long non-coding RNAs (lncRNAs) played crucial roles in various cancers. Nevertheless, study investigating lncRNA long intergenic non-protein coding RNA 1089 (LINC01089) in osteosarcoma is extremely rare. Thus, the research of LINC01089 is of great significance.

Materials and methods

qRT-PCR and western blot were done to test the expression of RNAs and proteins in osteosarcoma cells. Functional assays were carried out to evaluate biological behaviors of hFOB1.19 and osteosarcoma cells with or without LINC01089 knockdown and overexpression. In vitro and in vivo experiments in a rescue manner were performed to reveal the influences of LINC01089 and Hippo pathway on osteosarcoma cell phenotype and tumor growth.

Results

LINC01089 was down-regulated in osteosarcoma cells and overexpressing LINC01089 was validated to restrain cell growth in vitro and tumor growth in vivo. Additionally, silencing LINC01089 could exacerbate cell malignant behaviors. Correlation of LINC01089 and Hippo pathway was proved. Overexpressing LINC01089 could activate Hippo pathway to exert antitumor effects.

Conclusion

LINC01089 could restrain the progression of osteosarcoma through activating Hippo pathway.

Nur mit Berechtigung zugänglich

Cho Y, Jung GH, Chung SH, Kim JY, Choi Y, Kim JD (2011) Long-term survivals of stage IIb osteosarcoma: a 20 year experience in a single institution (in eng). Clin Orthop Surg 3:48–54. https://doi.org/10.4055/cios.2011.3.1.48CrossRefPubMedPubMedCentral

Savage SA, Mirabello L (2011) Using epidemiology and genomics to understand osteosarcoma etiology (in eng). Sarcoma 2011:548151. https://doi.org/10.1155/2011/548151CrossRefPubMedPubMedCentral

Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF (2011) The molecular pathogenesis of osteosarcoma: a review (in eng). Sarcoma 2011:959248. https://doi.org/10.1155/2011/959248CrossRefPubMedPubMedCentral

Mo JS, Park HW, Guan KL (2014) The hippo signaling pathway in stem cell biology and cancer (in eng). EMBO Rep 15:642–656. https://doi.org/10.15252/embr.201438638CrossRefPubMedPubMedCentral

Taha Z, Janse van Rensburg HJ, Yang X (2018) The hippo pathway: immunity and cancer (in eng). Cancers. https://doi.org/10.3390/cancers10040094CrossRefPubMedPubMedCentral

Jeong SH, Kim HB, Kim MC, Lee JM, Lee JH, Kim JH, Kim JW, Park WY, Kim SY, Kim JB, Kim H, Kim JM, Choi HS, Lim DS (2018) Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer (in eng). J Clin Investig 128:1010–1025. https://doi.org/10.1172/jci95802CrossRefPubMedPubMedCentral

Dong L, Lin F, Wu W, Liu Y, Huang W (2018) Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway (in eng). Int J Med Sci 15:645–652. https://doi.org/10.7150/ijms.23460CrossRefPubMedPubMedCentral

Hou L, Chen L, Fang L (2017) Scutellarin Inhibits proliferation, invasion, and tumorigenicity in human breast cancer cells by regulating HIPPO-YAP signaling pathway (in eng). Med Sci Monit 23:5130–5138. https://doi.org/10.12659/msm.904492CrossRefPubMedPubMedCentral

Renganathan A, Felley-Bosco E (2017) Long noncoding RNAs in cancer and therapeutic potential (in eng). Adv Exp Med Biol 1008:199–222. https://doi.org/10.1007/978-981-10-5203-3_7CrossRefPubMed

10.

Bhan A, Soleimani M, Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm (in eng). Can Res 77:3965–3981. https://doi.org/10.1158/0008-5472.Can-16-2634CrossRef

11.

Xiao J, Lv Y, Jin F, Liu Y, Ma Y, Xiong Y, Liu L, Zhang S, Sun Y, Tipoe GL, Hong A, Xing F, Wang X (2017) LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma (in eng). Cell physiol biochem 43:1926–1938. https://doi.org/10.1159/000484116CrossRefPubMed

12.

Wei GH, Wang X (2017) lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway (in eng). Eur Rev Med Pharmacol Sci 21:3850–3856PubMed

13.

Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Korner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F, Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Borresen-Dale AL, Yarden Y (2016) LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer (in eng). EMBO Mol Med 8:1052–1064. https://doi.org/10.15252/emmm.201606198CrossRefPubMedPubMedCentral

14.

Sinegubova MV, Orlova NA, Kovnir SV, Dayanova LK, Vorobiev II (2021) High-level expression of the monomeric SARS-CoV-2 S protein RBD 320–537 in stably transfected CHO cells by the EEF1A1-based plasmid vector (in eng). PLoS ONE 16:e0242890. https://doi.org/10.1371/journal.pone.0242890CrossRefPubMedPubMedCentral

15.

Dey A, Varelas X, Guan KL (2020) Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine (in eng). Nat Rev Drug Discov 19:480–494. https://doi.org/10.1038/s41573-020-0070-zCrossRefPubMedPubMedCentral

16.

Calses PC, Crawford JJ, Lill JR, Dey A (2019) Hippo pathway in cancer: aberrant regulation and therapeutic opportunities (in eng). Trends in cancer 5:297–307. https://doi.org/10.1016/j.trecan.2019.04.001CrossRefPubMed

17.

Al-Rugeebah A, Alanazi M, Parine NR (2019) MEG3: an Oncogenic long non-coding rna in different cancers (in eng). Pathol oncol res Pathology 25:859–874. https://doi.org/10.1007/s12253-019-00614-3CrossRef

18.

Zhang C, Hao Y, Wang Y, Xu J, Teng Y, Yang X (2018) TGF-β/SMAD4-regulated LncRNA-LINP1 inhibits epithelial-mesenchymal transition in lung cancer (in eng). Int J Biol Sci 14:1715–1723. https://doi.org/10.7150/ijbs.27197CrossRefPubMedPubMedCentral

19.

Liu K, Hou Y, Liu Y, Zheng J (2017) LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141 (in eng). J Biomed Sci 24:46. https://doi.org/10.1186/s12929-017-0353-9CrossRefPubMedPubMedCentral

20.

Qu G, Ma Z, Tong W, Yang J (2018) LncRNA WWOXAS1 inhibits the proliferation, migration and invasion of osteosarcoma cells (in eng). Mol Med Rep 18:779–788. https://doi.org/10.3892/mmr.2018.9058CrossRefPubMedPubMedCentral

21.

Wang W, Luo P, Guo W, Shi Y, Xu D, Zheng H, Jia L (2018) LncRNA SNHG20 knockdown suppresses the osteosarcoma tumorigenesis through the mitochondrial apoptosis pathway by miR-139/RUNX2 axis (in eng). Biochem Biophys Res Commun 503:1927–1933. https://doi.org/10.1016/j.bbrc.2018.07.137CrossRefPubMed

22.

Meng Z, Moroishi T, Guan KL (2016) Mechanisms of Hippo pathway regulation (in eng). Genes Dev 30:1–17. https://doi.org/10.1101/gad.274027.115CrossRefPubMedPubMedCentral

23.

Zygulska AL, Krzemieniecki K, Pierzchalski P (2017) Hippo pathway - brief overview of its relevance in cancer (in eng). J physiol pharmacol 68:311–335PubMed

24.

Fu V, Plouffe SW, Guan KL (2017) The Hippo pathway in organ development, homeostasis, and regeneration (in eng). Curr Opin Cell Biol 49:99–107. https://doi.org/10.1016/j.ceb.2017.12.012CrossRefPubMed

25.

Ahmed AA, Mohamed AD, Gener M, Li W, Taboada E (2017) YAP and the hippo pathway in pediatric cancer (in eng). Mol cell oncol 4:e1295127. https://doi.org/10.1080/23723556.2017.1295127CrossRefPubMedPubMedCentral

26.

Zhang M, Zhao Y, Zhang Y, Wang D, Gu S, Feng W, Peng W, Gong A, Xu M (2018) LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway (in eng). Biochim Biophys Acta 1864:1770–1782. https://doi.org/10.1016/j.bbadis.2018.03.005CrossRef

27.

Wu DM, Wang S, Wen X, Han XR, Wang YJ, Shen M, Fan SH, Zhang ZF, Shan Q, Li MQ, Hu B, Lu J, Chen GQ, Zheng YL (2018) LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma (in eng). Cell Death Dis 9:947. https://doi.org/10.1038/s41419-018-0975-1CrossRefPubMedPubMedCentral

28.

Zhao W, Zhang LN, Wang XL, Zhang J, Yu HX (2019) Long noncoding RNA NSCLCAT1 increases non-small cell lung cancer cell invasion and migration through the hippo signaling pathway by interacting with CDH1 (in eng). FASEB J 33:1151–1166. https://doi.org/10.1096/fj.201800408RCrossRefPubMed

Titel: The crosstalk between LINC01089 and hippo pathway inhibits osteosarcoma progression
verfasst von: Hao Zhang
Lin Zhou
Shaopu Hu
Wei Gu
Zhiqiang Li
Jun Sun
Xiaoen Wei
Yongjun Wang
Publikationsdatum: 18.11.2022
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 6/2022
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01377-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Bone mass and biomarkers in young women with anorexia nervosa: a prospective 3-year follow-up study

Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis

A novel serological biomarker are associated with disease severity in patients with osteoarthritis

Selenium-sensitive histone deacetylase 2 is required for forkhead box O3A and regulates extracellular matrix metabolism in cartilage

Study on mass transfer in the bone lacunar-canalicular system under different gravity fields